Its action is specific to adipocytes (fat cells) via beta-3 adrenergic receptors and does not affect anabolic pathways, protein synthesis signaling, or IGF-1 levels
To an extent, thats true
Or bought in a bundle of 14 shots then works out to be 25 each shot
Too much NNMT can lower NAD+ levels (low NAD+ levels may make it harder to burn fat efficiently or maintain metabolic health as you age)

Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome

Gently push the needle into the skin until it wont go any further Step 18